Swiss luxury watchmakers' shares drop after Trump tariff shock
GENEVA : Swiss luxury watchmakers' shares, including Richemont and Swatch, were volatilein early trade today, underscoring the challenges for the industry after US President Donald Trump imposed a 39% tariff on Swiss imports.
The sector, which exported watches worth CHF26 billion (US$32.79 billion) in 2024, is already under pressure from a stronger franc and falling global demand.
Watch exports are on track to hit their lowest levels since the pandemic in 2020.
Shares in Richemont and Swatch were both down 0.8% at 8.25am, paring back losses after earlier falling as much as 3.4%, and 5%, respectively.
Today was the first day of trading following the US tariff announcement, as markets were closed on Friday for the Swiss National Day.
'The impact of the US tariffs, if they stay at 39%, could be devastating for numerous brands in Switzerland,' said Jean-Philippe Bertschy, an analyst at Vontobel.
'We expect a strong negative impact for watches in the entry- to mid-price segments,' he said.
The US is Switzerland's leading foreign market for watches, accounting for 16.8% of exports worth about CHF4.4 billion (US$5.45 billion), according to the Federation of the Swiss Watch Industry.
Shahzaib Khan, who runs a business exporting Swiss luxury watches, said many brands would not be able to deal with the 39% tariff rate.
'I suspect … there won't be any goods being shipped to the US until the situation clears,' he said.
'While Richemont generated 32% of its full-year 2025 sales in the watches category, its exposure to the US market should be just below 10% of overall sales,' analysts at Jefferies said.
Swatch, meanwhile, generated 18% of its 2024 sales in the US, with its CEO saying the company had raised prices by 5% following the first tariffs announcement in April.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
2 hours ago
- The Sun
Malaysia sets sights on becoming Asean pharmaceutical and healthcare hub
KUALA LUMPUR: Malaysia is setting its sights on becoming a halal pharmaceutical and healthcare hub for Asean, leveraging partnerships with India's booming pharma sector as industry leaders prepare for the Second Malaysia Pharma and Healthcare Expo (MPHC 2025) in October. The expo, to be held at the World Trade Centre Kuala Lumpur from Oct 7 to 9, is expected to attract over 100 companies, up from 70 last year, alongside policymakers, researchers and investors across Asean, India, Australia and South Korea. Organisers say the event will spotlight innovations in halal-certified drugs, active pharmaceutical ingredients (APIs), biotech, regenerative medicine, telehealth and AI-driven diagnostics. Malaysia-India Business Council general secretary Datuk Surendran Menon said trade between Malaysia and India stood at US$20 billion (RM84.6 billion) in 2024, but pharmaceuticals made up just US$96–$104 million of that figure, a sign of significant untapped potential. 'India is known as the pharma of the world, while Malaysia offers halal regulation expertise and a strategic Asean strong potential in contract manufacturing, technology transfer and joint R&D, especially in halal pharmaceuticals and vaccines,' Surendran told reporters at a media briefing today. He said Malaysia imports over 70% of its pharmaceutical products, and the government's national pharmaceutical policy is pushing for greater domestic production, a move that could entice Indian firms seeking to expand into Asean markets. He also pointed to India's own 200 million-strong Muslim population as an untapped market for halal pharma products manufactured in Malaysia. 'Even if we tap just 50 million of that halal market in India, it's far larger than our domestic market here. Halal-certified medicines made in Malaysia could be exported not just across Asean but also back into India itself,' he said. This strategy, he added, would allow two-way investment flows, Indian companies bringing R&D and cost efficiencies to Malaysia, while Malaysian firms could set up manufacturing or joint ventures in India. Asean-India Economic Council chairman Datuk Ramesh Kodammal said Malaysia stands to benefit from India's US$50 billion pharmaceutical export industry, particularly as Asean and India review their free trade agreement, which has been in place for 11 years. 'If we work closely with India, we will have a lot of benefit,' he said, adding Malaysia has a great advantage of re-exporting with these Indian companies for the Asean market a huge market of 700 million people. Ramesh confirmed 40 Indian companies are slated to participate in MPHC 2025, alongside Asean, Australian and South Korean firms.
Malay Mail
2 hours ago
- Malay Mail
What happens next in the US court battle over Trump's tariffs?
WASHINGTON, Aug 5 — A federal appeals panel on Thursday appeared sceptical of US President Donald Trump's argument that a 1977 law historically used for sanctioning enemies or freezing their assets gave him the power to impose tariffs. Regardless of how the court rules, the litigation is almost certainly headed to the US Supreme Court. Here is what you need to know about the dispute, which Trump has called 'America's big case,' and how it is likely to play out in the months ahead. What is the case about? The litigation challenges the tariffs Trump imposed on a broad range of US trading partners in April, as well as tariffs imposed in February against China, Canada and Mexico. It centres around Trump's use of the International Emergency Economic Powers Act (IEEPA), which gives the president the power to address 'unusual and extraordinary' threats during national emergencies. Trump has said that trade imbalances, declining manufacturing power and the cross-border flow of drugs justified the tariffs under IEEPA. A dozen Democratic-led states and five small US businesses challenging the tariffs argue that IEEPA does not cover tariffs and that the US Constitution grants Congress, not the president, authority over tariffs and other taxes. A loss for Trump would also undermine the latest round of sweeping tariffs on dozens of countries that he unveiled late Thursday. Trump has made tariffs a cornerstone of his economic plan, arguing they will promote domestic manufacturing and substitute for income taxes. What's the status of the litigation? The US Court of Appeals for the Federal Circuit heard oral arguments on Thursday in the case. The panel of 11 judges sharply questioned the government about Trump's use of IEEPA, but did not rule from the bench. The Federal Circuit has not said when it will issue a decision, but its briefing schedule suggests it intends to move quickly. Meanwhile, the tariffs remain in effect after the Federal Circuit paused a lower court's ruling declaring them illegal. Will Trump's tariffs be blocked if he loses in court? A Federal Circuit ruling would almost certainly not end the litigation, as the losing party is expected to appeal to the Supreme Court. If the Federal Circuit rules against Trump, the court could put its own ruling on hold while the government appeals to the Supreme Court. This approach would maintain the status quo and allow the nine justices to consider the matter more thoroughly. The justices themselves could also issue an 'administrative stay' that would temporarily pause the Federal Circuit's decision while it considers a request from the Justice Department for more permanent relief. Is the Supreme Court likely to step in? The Supreme Court is not obligated to review every case appealed to it, but it is widely expected to weigh in on Trump's tariffs because of the weighty constitutional questions at the heart of the case. If the Federal Circuit rules in the coming weeks, there is still time for the Supreme Court to add the case to its regular docket for the 2025-2026 term, which begins on October 6. The Supreme Court could rule before the end of the year, but that would require it to move quickly. How might the Supreme Court rule? There is no consensus among court-watchers about what the Supreme Court will do. Critics of Trump's tariffs are optimistic their side will win. They point to the Supreme Court's decision from 2023 that blocked President Joe Biden from forgiving student loan debt. In that ruling, the justices limited the authority of the executive branch to take action on issues of 'vast economic and political significance' except where Congress has explicitly authorized the action. The justices in other cases, however, have endorsed a broad view of presidential power, especially when it comes to foreign affairs. Can importers seek refunds for tariffs paid? If Trump loses at the Supreme Court, importers are likely to seek refunds of tariffs already paid. This would be a lengthy process given the large number of anticipated claims. Federal regulations dictate that such requests would be first heard by US Customs and Border Protection. If that agency denies a refund request, the importer can appeal to the Court of International Trade. There is precedent for tariff refund requests being granted. Since May, CBP has been processing refunds to importers who inadvertently overpaid duties because of tariff 'stacking' — where multiple overlapping tariffs are applied to the same imports. And in the 1990s, after the Court of International Trade struck down a tax on exporters that was being used to finance improvements to US harbours, the court set up a process for issuing refunds. That decision was upheld by both the Federal Circuit and the Supreme Court. Would a courtroom defeat unravel Trump's trade deals? Trump has used the threat of emergency tariffs as leverage to secure concessions from trading partners. A loss at the Supreme Court would hamstring Trump in future negotiations. The White House, however, has other ways of imposing tariffs, like a 1962 law that allows the president to investigate imports that threaten national security. Trump has already used that law to put tariffs on steel and aluminium imports, and those levies are not at issue in the case before the Federal Circuit. Some legal experts say a loss for Trump at the Supreme Court would not impact bilateral trade agreements the US has already inked with other countries. Others say that the trade deals alone might not provide sufficient legal authority for taxes on imports and may need to be approved by Congress. — Reuters
The Sun
3 hours ago
- The Sun
Israel to partially reopen Gaza private goods trade amid aid crisis
JERUSALEM: Israel will partially reopen private sector trade with Gaza to reduce dependence on humanitarian aid, the defence ministry's civil affairs agency COGAT announced on Tuesday. The move follows months of blockade and conflict with Hamas, which has left Gaza in dire need of basic supplies. 'As part of formulating the mechanism, a limited number of local merchants were approved by the defence establishment, subject to several criteria and strict security screening,' COGAT said. Israel imposed a total blockade on Gaza in March but partially lifted restrictions in May to allow a US-backed private agency to distribute food. Despite resumed aid convoys and airdrops by Arab and European nations, UN experts warn famine is spreading in the war-torn enclave. The new trade mechanism will permit food staples, fruit, vegetables, baby formula, and hygiene products. Deliveries will undergo military inspections to prevent Hamas involvement, with payments made via monitored bank transfers. COGAT reported over 300 aid trucks entered Gaza on Monday, more than recent days, though Hamas disputed the figures, claiming only 95 trucks arrived, many looted amid alleged Israeli-instigated chaos. The UN estimates 500-600 daily truckloads are needed to sustain Gaza's population. - AFP
